

CITATION REPORT

List of articles citing

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

DOI: 10.1136/ard.2004.020875

Annals of the Rheumatic Diseases, 2004, 63, 1594-600.

Source: <https://exaly.com/paper-pdf/36554456/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 243 | Treatment update on spondyloarthritis. 2005 , 17, 247-56 | | 23 |
| 242 | Management and treatment of ankylosing spondylitis. 2005 , 17, 418-25 | | 12 |
| 241 | [Early diagnosis of spondyloarthritis with special attention to the axial forms]. 2005 , 64, 524-30 | | 5 |
| 240 | The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. 2005 , 52, 2506-12 | | 79 |
| 239 | Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 2005 , 52, 3898-909 | | 69 |
| 238 | Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. 2005 , 53, 856-63 | | 121 |
| 237 | Novel therapies for ankylosing spondylitis. 2005 , 7, 182-7 | | 1 |
| 236 | Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1557-62 | 2.4 | 120 |
| 235 | Etanercept: an introduction. <i>Expert Review of Clinical Immunology</i> , 2005 , 1, 313-23 | 5.1 | 2 |
| 234 | [Not Available]. 2005 , 1, 32-7 | | 4 |
| 233 | [Not Available]. 2005 , 1 Suppl 1, S46-50 | | |
| 232 | [Effectiveness of biological agents in ankylosing spondylitis]. 2005 , 1 Suppl 2, S24-41 | | 2 |
| 231 | How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 4, iv61-4 | 2.4 | 20 |
| 230 | [Spondylarthropathies and anti-TNFalpha drugs]. 2005 , 26, 717-24 | | 3 |
| 229 | Pharmacological treatment of ankylosing spondylitis: a systematic review. 2005 , 65, 2111-27 | | 20 |
| 228 | A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. 2006 , 2, 546-53 | | 70 |
| 227 | ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 442-52 | 2.4 | 431 |

| | | | |
|-----|--|-----|-----|
| 226 | Use NSAIDs to relieve pain and stiffness in patients with ankylosing spondylitis and reserve tumour necrosis factor- α antagonists for NSAID-refractory patients. 2006 , 22, 11-14 | | |
| 225 | Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. 2006 , 7, 869-83 | | 2 |
| 224 | Newer therapeutic approaches: spondyloarthritis and uveitis. 2006 , 32, 75-90, viii | | 8 |
| 223 | [Not Available]. 2006 , 2, 78-89 | | 9 |
| 222 | Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1473-7 | 2.4 | 56 |
| 221 | Diagnosis and management of ankylosing spondylitis. 2006 , 333, 581-5 | | 56 |
| 220 | Anti-TNF-alpha therapy in ankylosing spondylitis. 2006 , 33, 294-8 | | 14 |
| 219 | Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. 2006 , 18, 347-53 | | 26 |
| 218 | Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?. 2006 , 36, 72-6 | | 4 |
| 217 | [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. 2006 , 65, 728-42 | | 11 |
| 216 | The treatment of the rheumatological manifestations of the inflammatory bowel diseases. 2006 , 26, 953-8 | | 11 |
| 215 | Ankylosing spondylitis: new treatment modalities. 2006 , 20, 559-70 | | 9 |
| 214 | Ankylosing spondylitis. 2006 , 34, 396-400 | | 5 |
| 213 | Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. 2006 , 54, 2136-46 | | 630 |
| 212 | Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. 2006 , 55, 812-6 | | 37 |
| 211 | Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis. 2006 , 2, 211-8 | | 16 |
| 210 | Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65 Suppl 3, iii25-8 | 2.4 | 4 |
| 209 | Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1572-7 | 2.4 | 81 |

| | | | |
|-----|--|-----|------|
| 208 | A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 124-7 | 2.4 | 13 |
| 207 | Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 423-32 | 2.4 | 133 |
| 206 | First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 316-20 | 2.4 | 229 |
| 205 | Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007 , 11, S3-S13 | 1.6 | 1 |
| 204 | Adalimumab for the treatment of ankylosing spondylitis. 2007 , 8, 831-8 | | 12 |
| 203 | Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. 2007 , 8, 1373-97 | | 7 |
| 202 | Emerging biologics in the treatment of uveitis. <i>Expert Review of Clinical Immunology</i> , 2007 , 3, 781-96 | 5.1 | 3 |
| 201 | Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 2007 , 7, 155-69 | | 2 |
| 200 | New therapeutic approaches for spondyloarthritis. 2007 , 19, 259-64 | | 11 |
| 199 | Ankylosing spondylitis. 2007 , 369, 1379-1390 | | 1210 |
| 198 | [Not Available]. 2007 , 3 Suppl 2, S51-4 | | 1 |
| 197 | [Not Available]. 2007 , 3 Suppl 2, S60-70 | | 12 |
| 196 | [Meta-analysis of efficacy of anti-TNF alpha therapy in ankylosing spondylitis patients]. 2007 , 3, 204-12 | | 4 |
| 195 | Tumor necrosis factor as a therapeutic target of rheumatologic disease. 2007 , 11, 1369-84 | | 45 |
| 194 | Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 936-9 | 2.4 | 112 |
| 193 | Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis. 2007 , 67, 2609-33 | | 14 |
| 192 | Meta-Analysis of Efficacy of Anti-TNF Alpha Therapy in Ankylosing Spondylitis Patients. 2007 , 3, 204-212 | | |
| 191 | Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. 2007 , 57, 639-47 | | 139 |

| | | | |
|-----|---|-----|-----|
| 190 | Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment. 2007 , 36, 210-23 | | 33 |
| 189 | Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. 2007 , 26, 1693-700 | | 21 |
| 188 | Advances in the diagnosis and immunotherapy for ocular inflammatory disease. 2008 , 30, 145-64 | | 23 |
| 187 | [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis]. 2008 , 158, 200-5 | | 3 |
| 186 | ThÉrapie occupationnelle dans la spondylarthrite ankylosante : Étude prospective à court terme chez des patients traités par anti-TNF. 2008 , 75, 32-36 | | |
| 185 | RÉponse à six mois aux anti-TNF dans les formes axiales de spondylarthropathies selon la satisfaction ou non des critères de New-York et des recommandations de la Société Française de rhumatologie. Étude rétrospective de 175 patients. 2008 , 75, 1220-1228 | | |
| 184 | Infliximab in severe active ankylosing spondylitis with spinal ankylosis. 2008 , 38, 396-401 | | 14 |
| 183 | Tumour necrosis factor inhibitors in ankylosing spondylitis. 2008 , 38, 781-9 | | 14 |
| 182 | TNFalpha blockade in human diseases: an overview of efficacy and safety. 2008 , 126, 13-30 | | 194 |
| 181 | Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. 2008 , 75, 29-33 | | 25 |
| 180 | Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients. 2008 , 75, 680-7 | | 12 |
| 179 | Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. 2008 , 38, 83-100 | | 20 |
| 178 | ¿CÓmo hay que administrar los aine en la espondilitis anquilosante?. 2008 , 9, 137-143 | | |
| 177 | Nonsurgical management of ankylosing spondylitis. 2008 , 24, E5 | | 4 |
| 176 | Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. <i>Rheumatology</i> , 2008 , 47, 1054-7 | 3.9 | 17 |
| 175 | Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. 2008 , 178, 948-55 | | 269 |
| 174 | Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. <i>Rheumatology</i> , 2009 , 48, 551-7 | 3.9 | 20 |
| 173 | Update on the use of etanercept across a spectrum of rheumatoid disorders. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 165-73 | 4.4 | 8 |

| | | | |
|-----|---|-----|-----|
| 172 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 229-52 | 4.4 | 16 |
| 171 | Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. 2008 , 23, 852-6 | | 13 |
| 170 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. 2009 , 1, 163-178 | | 3 |
| 169 | The Treatment of Ankylosing Spondylitis and Psoriatic Arthritis with Etanercept: A Comprehensive Review. 2009 , 1, CMT.S37 | | |
| 168 | Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. 2009 , 22, 1125-9 | | 26 |
| 167 | Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 922-9 | 2.4 | 116 |
| 166 | 'It's magic stuff': the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication. 2009 , 7, 162-77 | | 10 |
| 165 | Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? 2009 , 61, 801-12 | | 35 |
| 164 | Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. 2009 , 61, 966-73 | | 48 |
| 163 | A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. 2009 , 29, 1123-35 | | 28 |
| 162 | Etanercept in the longterm treatment of patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2009 , 36, 1256-64 | 4.1 | 43 |
| 161 | Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2009 , 36, 801-8 | 4.1 | 158 |
| 160 | Espondilitis anquilosante. 2009 , 10, 1994-2000 | | |
| 159 | Therapy of spondyloarthritides. 2009 , 649, 133-47 | | 9 |
| 158 | A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. 2010 , 30, 1437-40 | | 36 |
| 157 | Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. 2010 , 29, 1149-54 | | 32 |
| 156 | Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. 2010 , 62, 1362-9 | | 69 |
| 155 | Critères de réponse dans les spondylarthropathies: définition d'un répondeur. 2010 , 77, 52-58 | | |

| | | | |
|-----|---|-----|-----|
| 154 | Management of Ankylosing Spondylitis and Other Spondyloarthropathies. 2010 , 46-54 | | |
| 153 | Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. <i>Rheumatology</i> , 2010 , 49, 1578-89 | 3-9 | 18 |
| 152 | Fatigue in rheumatic disease: an overview. 2010 , 5, 487-502 | | 38 |
| 151 | Indian Rheumatology Association consensus statement on the diagnosis and treatment of axial spondyloarthropathies. 2010 , 5, 16-34 | | 9 |
| 150 | Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. <i>Arthritis Research and Therapy</i> , 2010 , 12, R117 | 5-7 | 72 |
| 149 | Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R43 | 5-7 | 22 |
| 148 | Spondyloarthritides: evolving therapies. <i>Arthritis Research and Therapy</i> , 2010 , 12, 221 | 5-7 | 12 |
| 147 | Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. <i>Arthritis Research and Therapy</i> , 2011 , 13 Suppl 1, S4 | 5-7 | 67 |
| 146 | Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. 2011 , 40, 183-91 | | 7 |
| 145 | Anti-TNF α therapy in ankylosing spondylitis: symptom control and structural damage modification. 2011 , 7, 51-55 | | |
| 144 | Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in Spondyloarthritis except for Psoriatic Arthritis. 2011 , 7, 113-123 | | 1 |
| 143 | [Anti-TNF α therapy in ankylosing spondylitis: symptom control and structural damage modification]. 2011 , 7, 51-5 | | 2 |
| 142 | [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis]. 2011 , 7, 113-23 | | 34 |
| 141 | Comment définir l'activité d'une spondylarthrite ?. 2011 , 78, S215-S224 | | |
| 140 | Adverse effects of biologics: a network meta-analysis and Cochrane overview. 2011 , CD008794 | | 353 |
| 139 | Biologics in children's autoimmune disorders: efficacy and safety. 2011 , 170, 157-67 | | 32 |
| 138 | Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. 2011 , 31, 233-8 | | 18 |
| 137 | Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. 2011 , 63, 1543-51 | | 103 |

| | | | |
|-----|---|-----|----|
| 136 | New considerations in the design of clinical trials for spondyloarthritis. 2011 , 1, 1505-1512 | | |
| 135 | Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. 2011 , 51, 864-75 | | 13 |
| 134 | High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). <i>Rheumatology</i> , 2011 , 50, 1828-37 | 3.9 | 29 |
| 133 | Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2011 , 38, 1644-50 | 4.1 | 31 |
| 132 | Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies. <i>Rheumatology</i> , 2011 , 50, 714-20 | 3.9 | 32 |
| 131 | Compliance with NICE guidance on the use of anti-TNF α agents in ankylosing spondylitis: an east and west Midlands regional audit. 2012 , 12, 324-7 | | 3 |
| 130 | Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. <i>Rheumatology</i> , 2012 , 51, 243-9 | 3.9 | 30 |
| 129 | Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. 2012 , 15, 1054-63 | | 30 |
| 128 | Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy. 2012 , 10, 230-5 | | 3 |
| 127 | Diagnosis and treatment of juvenile spondyloarthropathy and related diseases. 2012 , 41, | | 1 |
| 126 | Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. <i>Rheumatology</i> , 2012 , 51, 1687-96 | 3.9 | 21 |
| 125 | Rheumatoid Arthritis and Ankylosing Spondylitis. 2012 , 169-195 | | |
| 124 | Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. <i>Journal of Rheumatology</i> , 2012 , 39, 836-40 | 4.1 | 20 |
| 123 | Dosage adjustment of anti-tumor necrosis factor- α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. <i>Journal of Rheumatology</i> , 2012 , 39, 1418-23 | 4.1 | 28 |
| 122 | Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. 2012 , 31, 1677-82 | | 11 |
| 121 | Los anti-TNF y la progresi3n radiogr3fica en espondilitis anquilosante. 2012 , 19, 8-17 | | |
| 120 | Etanercept: efficacy and safety for approved indications. 2012 , 11, 121-39 | | 55 |
| 119 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. 2012 , 142, e1S-e111S | | 37 |

| | | | |
|-----|---|-----|-----|
| 118 | Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R53 | 5-7 | 22 |
| 117 | The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. 2012 , 32, 2271-4 | | 10 |
| 116 | Fatigue in ankylosing spondylitis: causes, consequences and self-management. 2013 , 11, 39-50 | | 28 |
| 115 | Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice. 2013 , 6, 185 | | 13 |
| 114 | Patient perspectives of managing fatigue in Ankylosing Spondylitis, and views on potential interventions: a qualitative study. 2013 , 14, 163 | | 18 |
| 113 | Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. 2013 , 23, 497-506 | | 16 |
| 112 | Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1221-4 | 2-4 | 82 |
| 111 | Recomendações sobre diagnóstico e tratamento da espondilite anquilosante. 2013 , 53, 242-257 | | 14 |
| 110 | Fatigue in ankylosing spondylitis: treatment should focus on pain management. 2013 , 42, 361-7 | | 38 |
| 109 | Recommendations for the management and treatment of ankylosing spondylitis. 2013 , 53, 242-257 | | |
| 108 | Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. 2013 , 33, 2199-213 | | 68 |
| 107 | Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. 2013 , 31, 415-25 | | 21 |
| 106 | Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. 2013 , 35, 1376-85 | | 23 |
| 105 | Tumor necrosis factor γ inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. 2013 , 65, 3096-106 | | 109 |
| 104 | Efficacy of antitumor necrosis factor (γ) agents on patients with ankylosing spondylitis. 2013 , 346, 455-61 | | 11 |
| 103 | Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. 2013 , 41, 1150-9 | | 12 |
| 102 | Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. <i>Biologics: Targets and Therapy</i> , 2013 , 7, 1-6 | 4-4 | 42 |
| 101 | Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. 2013 , 7, 961-72 | | 21 |

| | | | |
|-----|---|-----|----|
| 100 | Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. 2014 , 8, 1585-1592 | | 8 |
| 99 | Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. 2014 , 43, 49-53 | | 23 |
| 98 | Effectiveness of tumor necrosis factor inhibitors in early axial spondyloarthritis: data from the DESIR cohort. 2014 , 66, 1734-44 | | 25 |
| 97 | [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. 2014 , 73 Suppl 2, 78-96 | | 3 |
| 96 | Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors. 2014 , 34, 979-86 | | 6 |
| 95 | Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. 2014 , 15 Suppl 1, S45-52 | | 21 |
| 94 | Brief Report: Nonsteroidal Antiinflammatory Drug-Sparing Effect of Tumor Necrosis Factor Inhibitors in Early Axial Spondyloarthritis: Results From the DESIR Cohort. 2015 , 67, 2363-8 | | 10 |
| 93 | Tumor necrosis factor inhibitor therapy in ankylosing spondylitis: differential effects on pain and fatigue and brain correlates. 2015 , 156, 297-304 | | 33 |
| 92 | Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial. <i>Journal of Rheumatology</i> , 2015 , 42, 1177-85 | 4.1 | 29 |
| 91 | Tumor Necrosis Factor-Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome. <i>Journal of Rheumatology</i> , 2015 , 42, 2376-82 | 4.1 | 14 |
| 90 | Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. 2015 , 35, 23-9 | | 10 |
| 89 | Drug survival of anti-tumour necrosis factor therapy in spondyloarthropathies: results from the Spanish emAR II Study. <i>Rheumatology</i> , 2015 , 54, 1459-63 | 3.9 | 14 |
| 88 | Factors affecting discontinuation of adalimumab and etanercept therapy in anti-TNF-naïve patients with ankylosing spondylitis: Nationwide population-based cohort study. <i>Modern Rheumatology</i> , 2015 , 25, 903-907 | 3.3 | |
| 87 | Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. <i>Rheumatology</i> , 2015 , 54, 1210-9 | 3.9 | 34 |
| 86 | Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials. <i>Journal of Rheumatology</i> , 2015 , 42, 1418-26 | 4.1 | 23 |
| 85 | TNF-alpha inhibitors for ankylosing spondylitis. 2015 , CD005468 | | 94 |
| 84 | Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. 2015 , 12, 317-25 | | 21 |
| 83 | Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2015 , 42, 2339-46 | 4.1 | 37 |

| | | | |
|----|--|-----|-----|
| 82 | Efficacy of TNF blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1241-8 | 2.4 | 139 |
| 81 | An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis. 2016 , 10, 2255-62 | | |
| 80 | Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis. 2016 , 95, e3060 | | 20 |
| 79 | Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. 2016 , 36, 643-51 | | 7 |
| 78 | Rheumatoid Arthritis and Spondyloarthritis. 2016 , 181-215 | | |
| 77 | Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. 2016 , 29, 510-5 | | 11 |
| 76 | Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor- α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis. 2016 , 3, 323-336 | | 8 |
| 75 | Efficacy and safety of TNF inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. 2016 , 6, 32768 | | 19 |
| 74 | Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?. 2017 , 37, 327-336 | | 7 |
| 73 | Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1036-1041 | 2.4 | 16 |
| 72 | DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS. 2017 , 33, 69-75 | | 5 |
| 71 | Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective. 2017 , 4, 427-443 | | 5 |
| 70 | Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials. 2017 , 14, 3491-3500 | | 12 |
| 69 | Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study. 2017 , 7, 13165 | | 6 |
| 68 | Etanercept for treating axial spondyloarthritis. 2017 , 17, 1173-1181 | | 9 |
| 67 | Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis. 2017 , 96, e7145 | | 16 |
| 66 | Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. 2017 , 36, 1569-1577 | | 10 |
| 65 | Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. <i>Rheumatology</i> , 2018 , 57, 880-890 | 3.9 | 3 |

| | | | |
|----|--|-----|----|
| 64 | Comparative Efficacy of Tumor Necrosis Factor- α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis. <i>Journal of Rheumatology</i> , 2018 , 45, 481-490 | 4.1 | 17 |
| 63 | Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. 2018 , 37, 439-450 | | 8 |
| 62 | The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials. 2018 , 54, 234-243 | | 12 |
| 61 | Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2018 , 57, 419-428 | 3.9 | 10 |
| 60 | An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. 2018 , 32, 453-471 | | 13 |
| 59 | Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature. 2018 , 38, 2157-2162 | | 4 |
| 58 | Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry. 2018 , 5, 537-550 | | 8 |
| 57 | Beyond the TNF- α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology. 2018 , 78, 1397-1418 | | 10 |
| 56 | The value of contrast-enhanced ultrasonography to detect the sacroiliac joint for predicting relapse after discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. 2019 , 9, 1110-1117 | | 2 |
| 55 | Treatment Guidelines for Axial Spondyloarthritis. 2019 , 243-258 | | |
| 54 | 2018 APLAR axial spondyloarthritis treatment recommendations. 2019 , 22, 340-356 | | 26 |
| 53 | A prospective clinical investigation of the effects of anti-TNF alpha therapy on exercise capacity in patients with ankylosing spondylitis. 2019 , 49, 27-32 | | 2 |
| 52 | [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations]. 2019 , 78, 3-64 | | 5 |
| 51 | Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China. 2019 , 10, 1476 | | 1 |
| 50 | Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis. 2019 , 38, 465-475 | | 4 |
| 49 | The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. 2019 , 48, 997-1004 | | 11 |
| 48 | Recombinant expression, purification and bioactivity characterization of extracellular domain of human tumor necrosis factor receptor 1. <i>Protein Expression and Purification</i> , 2019 , 155, 21-26 | 2 | 5 |
| 47 | Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model. 2020 , 26, 1219-1231 | | 2 |

| | | | |
|----|--|------|----|
| 46 | Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020 , 59, 3158-3171 | 3.9 | 2 |
| 45 | Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long-term Results of Two Phase III Randomized Controlled Trials. 2020 , | | 3 |
| 44 | Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020 , 22, 177 | 5.7 | 6 |
| 43 | Placebo responses in ankylosing spondylitis patients worldwide: variations and possible explanations. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 447-450 | 5.1 | 1 |
| 42 | The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis - 2019. <i>Advances in Rheumatology</i> , 2020 , 60, 19 | 3 | 4 |
| 41 | Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , 2020 , 31, 724-744 | 10.3 | 64 |
| 40 | A Review of Drug-Drug Interactions for Biologic Drugs Used in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021 , 25, 38-44 | 1.6 | 2 |
| 39 | Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure. <i>Rheumatology</i> , 2021 , 60, 5743-5752 | 3.9 | 5 |
| 38 | Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials. <i>Statistics in Medicine</i> , 2021 , 40, 3385-3399 | 2.3 | 5 |
| 37 | Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2. <i>Protein Expression and Purification</i> , 2021 , 182, 105857 | 2 | 3 |
| 36 | Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 627-635 | 3 | 1 |
| 35 | Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2021 , 23, 192 | 5.7 | 1 |
| 34 | Efficacy and safety of biologics for the treatment of ankylosing spondylitis: systematic literature review and network meta-analysis of treatments registered in the Russian Federation. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021 , 58, 646-657 | 0.9 | 3 |
| 33 | Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis. <i>Modern Rheumatology</i> , 2010 , 20, 580-7 | 3.3 | 3 |
| 32 | Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012 , 22, 532-40 | 3.3 | 13 |
| 31 | Management of ankylosing spondylitis. 2011 , 1157-1177.e3 | | 2 |
| 30 | Anticytokine Therapies. 2013 , 957-977.e4 | | 1 |
| 29 | [Assessment of health-related quality of life of patients with chronic arthritis]. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2009 , 137, 684-9 | 0.2 | 1 |

| | | | |
|----|---|-----|----|
| 28 | Tumour necrosis factor- α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016 , 20, 1-334, v-vi | 4.4 | 49 |
| 27 | TNF-alpha inhibitors: Current indications. <i>Indian Journal of Critical Care Medicine</i> , 2007 , 11, 139-148 | 1.3 | 2 |
| 26 | Etanercept Treatment in Ankylosing Spondylitis Hip Lesions. <i>Hip and Pelvis</i> , 2013 , 25, 135 | 1.5 | 5 |
| 25 | Traitement de la spondylarthrite ankylosante par les agents anti-TNF α . <i>Bulletin De L'Academie Nationale De Medecine</i> , 2006 , 190, 981-994 | 0.1 | |
| 24 | Contribution de l'IRM des sacro-iliaques dans l'évaluation des spondylarthropathies sous infliximab (Étude prospective sur 34 patients). <i>Bulletin De L'Academie Nationale De Medecine</i> , 2006 , 190, 995-1005 | 0.1 | |
| 23 | [Biological therapy of arthritis and systemic autoimmune diseases]. <i>Orvosi Hetilap</i> , 2007 , 148 Suppl 1, 63-70 | 0.8 | 0 |
| 22 | Anticytokine Therapies. 2009 , 929-946 | | |
| 21 | Les thérapies ciblées des spondylarthrites. 2011 , 45-56 | | |
| 20 | Biologic Therapies. 2013 , 357-383 | | |
| 19 | Etanercept in rheumatology. 2006 , 45-54 | | |
| 18 | Biologic Therapies. 2008 , 403-427 | | |
| 17 | Treatment of ankylosing spondylitis: focus on etanercept. <i>Biologics: Targets and Therapy</i> , 2007 , 1, 45-51 | 4.4 | 2 |
| 16 | Challenges in the management of juvenile idiopathic arthritis with etanercept. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 127-39 | 4.4 | 16 |
| 15 | Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 322-30 | 2.2 | 10 |
| 14 | Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021 , | 5.9 | 1 |
| 13 | Relationship of adherence to treatment with disease activity, physical function, quality of life, treatment satisfaction and beliefs in axial spondyloarthritis patients. <i>Egyptian Rheumatologist</i> , 2022 , 44, 191-195 | 1 | 0 |
| 12 | Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort.. <i>RMD Open</i> , 2022 , 8, | 5.9 | |
| 11 | MRI in Axial Spondyloarthritis: Position Statements from the Hong Kong Society of Rheumatology. <i>Journal of Clinical Rheumatology and Immunology</i> , 1-7 | 0 | |

| | | | |
|----|---|------|---|
| 10 | ETANERCEPT IN PATIENTS WITH ANKYLOSING SPONDYLITIS: EFFECTIVENESS AND RATE OF RESPONSE. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> , | 0.2 | 0 |
| 9 | Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-Responder and Secondary Non-Responder of Prior TNF Inhibitor in Ankylosing Spondylitis.. <i>Modern Rheumatology</i> , 2022 , | 3.3 | 1 |
| 8 | Disease Activity-Guided Stepwise Tapering but Not Discontinuation of Biologics Is a Feasible Therapeutic Strategy for Patients with Ankylosing Spondylitis: Real-World Evidence.. <i>Advances in Therapy</i> , 2022 , 39, 1393 | 4.1 | 1 |
| 7 | Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis.. <i>JAMA Network Open</i> , 2022 , 5, e222312 | 10.4 | 0 |
| 6 | DataSheet_1.docx. 2019 , | | |
| 5 | Efficacy and Safety of Intravenous Golumumab in Ankylosing Spondylitis Patients With Early and Late Disease Through 1 Year of the GO-ALIVE Study. <i>Journal of Clinical Rheumatology</i> , 1 , Publish Ahead of Print, | 1.1 | 0 |
| 4 | The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents: BSRBR-AS and meta-analysis. <i>Journal of Rheumatology</i> , jrheum.211034 | 4.1 | |
| 3 | Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. 2022 , | | 0 |
| 2 | Seronegative spondyloarthropathy-associated inflammatory bowel disease. 29, 450-468 | | 0 |
| 1 | Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials. 14, | | 0 |